NEUROSCIENTIFIC BIOPHARMACEUTICALS LIMITED

NeuroScientific Biopharmaceuticals Limited

NSB

AU0000012973

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:05 2024-04-29 am EDT			5-day change	1st Jan Change
0.052 ^AUD	+8.33%		0.00%	+18.18%

Mar. 20	NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%	MT
Feb. 27	NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as CEO

September 08, 2022 at 07:48 pm EDT

NeuroScientific Biopharmaceuticals Ltd. announced the resignation of its CEO Mr. Matt Liddelow effective immediately.

Latest news about NeuroScientific Biopharmaceuticals Limited

NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%	Mar. 19	MT
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
NeuroScientific Biopharmaceuticals Limited Announces Changes to Board of Directors	Dec. 04	CI
NeuroScientific Biopharmaceuticals CEO to Step Down	Dec. 01	MT
NeuroScientific Biopharmaceuticals Limited Announces Resignation of Stephen Carter as CEO Effective 31 December 2023	Nov. 30	CI
Linda Friedland Steps Down from the Board of NeuroScientific Biopharmaceuticals Limited, Effective 17 November 2023	Nov. 15	CI
Neuroscientific Biopharmaceuticals Limited Announces Board Changes	Nov. 12	CI
NeuroScientific Biopharmaceuticals Ltd Appoints Linda Friedland as Independent Non-Executive Director	23-10-18	CI
Neuroscientific Biopharmaceuticals Limited Announces Chief Executive Officer Changes	23-08-30	CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-25	CI
Neuroscientific Biopharmaceuticals Announce Positive Treatment Effect in Multiple sclerosis Animal Study	23-03-13	CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Neuroscientific Biopharmaceuticals Files New Patent for Multiple Sclerosis Treatment; Shares Jump 7%	22-12-04	MT
NeuroScientific Biopharmaceuticals Files A New Patent, Entitled "Neuroprotective Compositions and Methods"	22-12-04	CI
NeuroScientific Biopharmaceuticals Names Interim CEO; Shares Climb 12%	22-11-22	MT
NeuroScientific Biopharmaceuticals Limited Announces Appointment of Mr. Paul Rennie as Interim CEO	22-11-22	CI
NeuroScientific Biopharmaceuticals Limited Announces Management Changes	22-11-15	CI
NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as Managing Director	22-09-08	CI
NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as CEO	22-09-08	CI
Neuroscientific Biopharmaceuticals Ltd. Announces HREC Decision to Not Approve Phase I Clinical Trial	22-09-06	CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29	CI
Neuroscientific Biopharmaceuticals Files Ethics Application for Phase 1 Trial of Neuroprotective Drug	22-07-11	MT
NeuroScientific Biopharmaceuticals Limited Announces Human Research Ethics Committee Submission for Phase I Clinical Trial	22-07-11	CI
Neuroscientific Recruits First Subject for Neurodegenerative Conditions Drug's Clinical Trial; Shares Rise 3%	22-06-29	MT
NeuroScientific Biopharmaceuticals Limited Announces Recruitment of First Subject Recruited for Early-Phase Clinical Trial	22-06-29	CI

Chart NeuroScientific Biopharmaceuticals Limited

Duration

Period

Chart NeuroScientific Biopharmaceuticals Limited

More charts

NeuroScientific Biopharmaceuticals Limited is an Australia-based company that is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Companyâs product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimerâs disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human bodyâs innate immune response to cell injury.

Sector

Biotechnology & Medical Research

Calendar

2024-08-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEUROSCIENTIFIC BIOPHARMACEUTICALS LIMITED	+18.18%	4.53M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.71%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B